Revenue and Profit Growth - Revenue for the first quarter of 2023 increased by 50.72% to RMB 193,286,953.47 compared to the same period last year[11] - Operating revenue for the first quarter of 2023 was RMB 193,286,953.47, a 50.7% increase compared to RMB 128,246,403.15 in the same period last year[33] - Net profit attributable to shareholders rose by 42.76% to RMB 39,922,932.84 year-over-year[11] - Net profit for the first quarter of 2023 was RMB 39,922,932.84, a 42.7% increase compared to RMB 27,964,503.94 in the same period last year[34] - The company's basic and diluted earnings per share both grew by 41.67% to RMB 0.17[11] - Basic earnings per share for the first quarter of 2023 were RMB 0.17, compared to RMB 0.12 in the same period last year[34] Cash Flow and Financial Position - Operating cash flow turned negative at RMB -15,751,558.42, a decrease of 126.77% from the previous year[11] - Net cash flow from operating activities turned negative at -15,751,558.42, compared to a positive 58,835,705.46 in the previous period[36] - Investment cash flow decreased significantly by 1,845.93% to RMB -15,747,092.81 due to payments for fundraising projects[16] - Net cash flow from investing activities was -15,747,092.81, a significant decrease from -809,231.50 in the previous period[36] - Cash and cash equivalents at the end of the first quarter of 2023 were RMB 1,825,739,376.30, a decrease of RMB 32,349,494.75 compared to the beginning of the period[31] - Monetary funds decreased to 1,825,739,376.30 yuan from 1,858,088,871.05 yuan at the beginning of the year[22] - Total liabilities and owner's equity at the end of the first quarter of 2023 were RMB 2,480,787,021.44, a slight decrease compared to RMB 2,497,721,443.51 at the end of the previous period[33] - Total assets slightly declined by 0.68% to RMB 2,480,787,021.44 compared to the end of the previous year[11] - Total assets decreased to 2,480,787,021.44 yuan from 2,497,721,443.51 yuan at the beginning of the year[22][23] R&D and Strategic Investments - R&D expenses increased by 53.89% to RMB 7,117,899.04 due to the company's "API + Formulation" integration strategy[16] - R&D expenses for the first quarter of 2023 were RMB 7,117,899.04, a 53.9% increase compared to RMB 4,625,339.65 in the same period last year[33] - Cash paid for the purchase of fixed assets, intangible assets, and other long-term assets increased sharply to 15,753,734.40 from 767,134.50[36] Assets and Liabilities - Current assets decreased to 2,198,104,491.56 yuan from 2,226,895,374.35 yuan at the beginning of the year[22] - Non-current assets increased to 282,682,529.88 yuan from 270,826,069.16 yuan at the beginning of the year[22][23] - Current liabilities decreased to 151,736,493.24 yuan from 208,909,427.09 yuan at the beginning of the year[23] - Non-current liabilities remained stable at 12,303,450.57 yuan compared to 12,312,563.79 yuan at the beginning of the year[23] - Shareholders' equity increased by 1.77% to RMB 2,316,747,077.63[11] - Shareholders' equity increased to 2,316,747,077.63 yuan from 2,276,499,452.63 yuan at the beginning of the year[23] - The company's total owner's equity at the end of the first quarter of 2023 was RMB 2,316,747,077.63, an increase of RMB 40,247,625.00 compared to the end of the previous period[33] Operating Activities and Expenses - Prepayments surged by 87.00% to RMB 34,389,436.84, driven by increased advance payments to suppliers[16] - Contract liabilities decreased by 59.88% to RMB 27,969,583.04 due to reduced prepayments from customers[16] - Sales of goods and services received cash of 140,480,784.29, an increase from the previous period's 129,945,261.07[36] - Cash received from other operating activities decreased to 13,439,650.24 from 19,657,544.73 in the previous period[36] - Total cash inflows from operating activities were 153,929,298.28, down from 158,915,828.76 in the previous period[36] - Cash paid for goods and services increased significantly to 100,153,085.60 from 57,535,278.18[36] - Cash paid to employees and for employee benefits rose to 27,871,641.79 from 22,166,248.58[36] - Total cash outflows from operating activities surged to 169,680,856.70 from 100,080,123.30[36] Financial Expenses and Other Items - The company's financial expenses for the first quarter of 2023 were RMB -11,607,887.42, mainly due to interest income of RMB 12,295,014.61[33] - Accounts receivable decreased to 70,891,650.90 yuan from 71,675,405.36 yuan at the beginning of the year[22] - Inventory increased to 122,046,297.99 yuan from 114,701,717.43 yuan at the beginning of the year[22] - Fixed assets decreased to 121,244,762.73 yuan from 126,308,041.13 yuan at the beginning of the year[22] - The company's first-quarter report for 2023 was unaudited[38]
亨迪药业(301211) - 2023 Q1 - 季度财报